Mr. Yan has over 20 years of experience specializing in cell signal transduction and cancer biology. He has expertise in high throughput screening against validated enzyme targets including protein kinases. Prior to co-founding SignalChem Pharmaceuticals Inc. in 2004, Mr. Yan held senior research positions at Kinetek Pharmaceuticals Inc. and QLT Inc., where he was playing leading roles in novel drug target validation and pipeline development of kinase inhibitors. With his leadership, Jun has built SignalChem Pharmaceuticals Inc into a very profitable business with higher than 20% annual increase in revenue which has been a leading supplier of cell signaling bioreagents for drug discovery and biomedical research. In 2010, Mr. Yan co-founded MetaSignal Therapeutics Inc., a company focusing on developing and commercializing anti-cancer drugs targeting CAIX, a well-known cancer related enzyme. Mr. Yan brings to SLC expertise in kinase biology and has been the driving force of the SLC’s kinase-focused drug discovery platform.
Dr. Zaihui Zhang is a co-founder of Signalchem Lifesciences Corporation. He has over 25 years of experience in the development of novel targeted therapies. He has successfully led a wide range of therapeutic programs across different disease areas and has experience working with different classes of biological targets including protein kinases, metallo-enzymes, sodium channels, and transporters. Dr. Zhang has led several therapeutic programs that have been successfully acquired by or partnered with top tier multinational pharmaceutical companies and biotech companies during his tenures at Xenon Pharmaceuticals Inc. and Kinetek Pharmaceuticals Inc.. He has played pivotal roles in advancing four small molecules from the discovery stage to the clinical stage. He is a co-author of more than 30 scientific publications and is an inventor/co-inventor of more than 80 patents and patent applications. He brings to SLC expertise in all stages of drug discovery including hit-to-lead, lead optimization, preclinical development, project management and leadership, and intellectual property. Dr. Zhang received his Ph.D. in chemistry from the University of British Columbia.
Mr. Quan has senior management experience in private and publicly traded companies for over 25 years. He has served as Senior Financial officer in many biotechnology companies and government funded institutes including Kinetek Pharmaceuticals Inc., Genome BC, Aquinox, Welichem Biotech and SignalChem. Harvey brings to SLC expertise in financial operations management for drug development and biotechnology companies.
Dr. Hong Zhang has over twenty years of experience in signal transduction, protein kinases and proteomics. He is an expert in disease-related signaling pathways and diagnostic biomarker and therapeutic target discovery. Dr. Zhang is a co-founder and CEO of Tel-Array, a cancer diagnostic company focused on precision medicine for cancer patients. Prior to joining Signalchem Lifesciences Corporation, Dr. Zhang was the Director of Research and Development at Kinexus Bioinformatics Corporation for more than 10 years. During his tenure at Kinexus, he oversaw the company’s research and development activities and spearheaded the development of a suite of proteomics microarray screening platforms including antibody, protein lysate and kinase microarrays, which have been widely adopted by the world leading pharmaceutical companies in their drug discovery and development programs. He has published a number of research papers in prestigious peer-reviewed journals and has authored several reviews and book chapters. Dr. Zhang received his Ph.D. degree in Cell and Molecular Biology from the University of British Columbia.
Dr. Zhiwei Xie has over two decades of experience in drug discovery and development. Prior to joining SignalChem LifeSciences Corp., Dr. Xie worked at Xenon Pharmaceuticals Inc. as a senior research scientist for over ten years. In this position, he made critical contributions to drug development for treatment of various diseases including anemia of inflammation, cardiovascular diseases, chronic pain and CNS disease. From 2004 to 2006, Dr. Xie worked at Inflazyme Pharmaceuticals Inc., where he was responsible for target identification and mechanism of action study of company’s lead anti-inflammatory compounds. He participated in evaluating and recruiting the technologies from Adprotech, a British biotech company. Before Inflazyme, Dr. Xie worked at Kinetek Pharmaceuticals Inc. and his main responsibility was the validation of kinases as therapeutic targets for developing drugs to treat the diseases such as cancer and inflammation. Dr. Xie received his Ph.D. in Biochemistry and Molecular Biology from Shanghai Institute of Biochemistry, Chinese Academy of Science and post-doctoral training in the Department of Biochemistry at the University of Washington in Seattle.